Immunovaccine, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Immunovaccine, Inc. – Product Pipeline Review – 2016’, provides an overview of the Immunovaccine, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunovaccine, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Immunovaccine, Inc.

The report provides overview of Immunovaccine, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Immunovaccine, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Immunovaccine, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Immunovaccine, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Immunovaccine, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Immunovaccine, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immunovaccine, Inc. Snapshot 5

Immunovaccine, Inc. Overview 5

Key Information 5

Key Facts 5

Immunovaccine, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Immunovaccine, Inc. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Immunovaccine, Inc. - Pipeline Products Glance 14

Immunovaccine, Inc. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Immunovaccine, Inc. - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Immunovaccine, Inc. - Drug Profiles 17

DPX-Survivac 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

DPX-RSV 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Vaccine for Cocaine Addiction 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

DPX-Ebola 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

DPXE-7 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

malaria vaccine 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Zika virus vaccine 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Immunovaccine, Inc. - Pipeline Analysis 27

Immunovaccine, Inc. - Pipeline Products by Target 27

Immunovaccine, Inc. - Pipeline Products by Route of Administration 28

Immunovaccine, Inc. - Pipeline Products by Molecule Type 29

Immunovaccine, Inc. - Recent Pipeline Updates 30

Immunovaccine, Inc. - Dormant Projects 36

Immunovaccine, Inc. - Discontinued Pipeline Products 37

Discontinued Pipeline Product Profiles 37

Pseudomonas vaccine 37

Immunovaccine, Inc. - Locations And Subsidiaries 38

Head Office 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Immunovaccine, Inc., Key Information 5

Immunovaccine, Inc., Key Facts 5

Immunovaccine, Inc. – Pipeline by Indication, 2016 7

Immunovaccine, Inc. – Pipeline by Stage of Development, 2016 8

Immunovaccine, Inc. – Monotherapy Products in Pipeline, 2016 9

Immunovaccine, Inc. – Partnered Products in Pipeline, 2016 10

Immunovaccine, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 11

Immunovaccine, Inc. – Out-Licensed Products in Pipeline, 2016 12

Immunovaccine, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Immunovaccine, Inc. – Phase II, 2016 14

Immunovaccine, Inc. – Phase I, 2016 15

Immunovaccine, Inc. – Preclinical, 2016 16

Immunovaccine, Inc. – Pipeline by Target, 2016 27

Immunovaccine, Inc. – Pipeline by Route of Administration, 2016 28

Immunovaccine, Inc. – Pipeline by Molecule Type, 2016 29

Immunovaccine, Inc. – Recent Pipeline Updates, 2016 30

Immunovaccine, Inc. – Dormant Developmental Projects,2016 36

Immunovaccine, Inc. – Discontinued Pipeline Products, 2016 37

List of Figures

List of Figures

Immunovaccine, Inc. – Pipeline by Top 10 Indication, 2016 7

Immunovaccine, Inc. – Pipeline by Stage of Development, 2016 8

Immunovaccine, Inc. – Monotherapy Products in Pipeline, 2016 9

Immunovaccine, Inc. – Partnered Products in Pipeline, 2016 10

Immunovaccine, Inc. – Pipeline by Target, 2016 27

Immunovaccine, Inc. – Pipeline by Route of Administration, 2016 28

Immunovaccine, Inc. – Pipeline by Molecule Type, 2016 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports